Karen Weintraub
@karenweintraub.bsky.social
Long-time health/science journalist, currently an editor at USA TODAY; lecturer in science journalism at MIT; co-author "Born in Cambridge: 400 Years of Ideas and Innovators."
Actually, the drug company in this case, but most pre-clinical research is government funded, and this was led by researchers at UCLA, a public university. www.nature.com/articles/s41...
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results - Nature Medicine
In the final analysis of a phase 1 trial evaluating a lymph node-targeting mutant KRAS peptide vaccine combined with CpG in the adjuvant setting for patients with KRAS mutant pancreatic or colorectal ...
www.nature.com
October 26, 2025 at 8:25 PM
Actually, the drug company in this case, but most pre-clinical research is government funded, and this was led by researchers at UCLA, a public university. www.nature.com/articles/s41...
Just listened to the audiobook version. SO compelling - and terrifying. Thanks for reading it yourself. Will have to check out the new introduction in the paperback.
August 5, 2025 at 2:38 AM
Just listened to the audiobook version. SO compelling - and terrifying. Thanks for reading it yourself. Will have to check out the new introduction in the paperback.
Reposted by Karen Weintraub
Due to legal threats and political pressure, Children’s National Hospital will “no longer will be prescribing medications, evaluating patients for or recommending medications, or providing services for monitoring of medications, including laboratory evaluations, for gender-affirming care.” 2/2
July 18, 2025 at 2:51 PM
Due to legal threats and political pressure, Children’s National Hospital will “no longer will be prescribing medications, evaluating patients for or recommending medications, or providing services for monitoring of medications, including laboratory evaluations, for gender-affirming care.” 2/2